- Ronopterin significantly reduces glutamate levels measured in brain microdialysate from TBI patients, an important and long sought indicator of biochemical neuroprotection
- Combined inhibition of nitric oxide synthesis and glutamate increase expands our understanding of Ronopterin’s mode of action and its association with improved outcome in TBI
- Decreasing glutamate adds to the previously reported reduction in aggressive therapeutic interventions and improved eGOS after moderate and severe TBI
- The glutamate-lowering potential of Ronopterin makes it an interesting candidate for other acute and chronic neurologic diseases involving activated inflammation and iNOS-driven glutamate increase
- New patent filed for Ronopterin-mediated glutamate reduction
Würzburg, Germany May 10, 2022: vasopharm GmbH (“vasopharm”), a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases, today announces the finding of statistically significantly reduced brain microdialysate glutamate levels in the phase 2 (NOSTRA) and phase 3 clinical trials (NOSTRA III) of Ronopterin (formerly VAS203) for the treatment of traumatic brain injury (TBI). This reduction in glutamate is of high importance as increased glutamate levels are associated with evolving cell damage and poor prognosis. These results expand on the reduced treatment aggressiveness and improved clinical outcome in patients with moderate and severe TBI with early infusion of Ronopterin after the injury. Ronopterin has the potential to be the first drug therapy for TBI with clinically meaningful improvements in biochemical changes and neurologic outcome.